Immunomedics, Inc. (NASDAQ:IMMU) Director Avoro Capital Advisors Llc bought 500,000 shares of the stock in a transaction on Monday, May 13th. The stock was purchased at an average cost of $15.07 per share, with a total value of $7,535,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Avoro Capital Advisors Llc also recently made the following trade(s):

  • On Wednesday, May 15th, Avoro Capital Advisors Llc bought 750,000 shares of Immunomedics stock. The stock was purchased at an average cost of $15.11 per share, with a total value of $11,332,500.00.

Shares of Immunomedics stock traded down $0.48 on Wednesday, hitting $14.93. The company had a trading volume of 2,055,043 shares, compared to its average volume of 3,111,805. The stock has a market capitalization of $2.95 billion, a PE ratio of -14.50 and a beta of 1.97. Immunomedics, Inc. has a twelve month low of $11.55 and a twelve month high of $27.33. The company has a quick ratio of 7.89, a current ratio of 7.89 and a debt-to-equity ratio of 0.04.

Immunomedics (NASDAQ:IMMU) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.10). During the same quarter in the prior year, the business posted ($0.21) EPS. Equities analysts anticipate that Immunomedics, Inc. will post -1.39 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Exane Derivatives acquired a new position in Immunomedics during the fourth quarter worth $32,000. Karp Capital Management Corp acquired a new position in Immunomedics during the fourth quarter worth $33,000. Global Retirement Partners LLC boosted its holdings in Immunomedics by 215.7% during the first quarter. Global Retirement Partners LLC now owns 1,910 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 1,305 shares during the last quarter. Cornerstone Advisors Inc. acquired a new position in Immunomedics during the first quarter worth $40,000. Finally, Pearl River Capital LLC acquired a new position in Immunomedics during the fourth quarter worth $66,000. Institutional investors and hedge funds own 86.11% of the company’s stock.

Several brokerages have commented on IMMU. Zacks Investment Research downgraded shares of Immunomedics from a “hold” rating to a “sell” rating in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $28.00 price target on shares of Immunomedics in a report on Monday. BidaskClub cut shares of Immunomedics from a “buy” rating to a “hold” rating in a report on Saturday, May 4th. ValuEngine cut shares of Immunomedics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, April 24th. Finally, Piper Jaffray Companies set a $20.00 price target on shares of Immunomedics and gave the company a “buy” rating in a report on Monday, April 8th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $28.45.

COPYRIGHT VIOLATION NOTICE: “Insider Buying: Immunomedics, Inc. (IMMU) Director Purchases 500,000 Shares of Stock” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.thecerbatgem.com/2019/05/15/insider-buying-immunomedics-inc-immu-director-purchases-500000-shares-of-stock.html.

About Immunomedics

Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.

See Also: How Do Front-End Loads Impact an Investment?

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.